Cargando…
Status of group B streptococcal vaccine development
Streptococcus agalactiae (group B streptococcus, GBS) is a leading causal organism of neonatal invasive diseases and severe infections in the elderly. Despite significant advances in the diagnosis and treatment of GBS infections and improvement in personal hygiene standards, this pathogen is still a...
Autores principales: | Lin, Shun Mei, Zhi, Yong, Ahn, Ki Bum, Lim, Sangyong, Seo, Ho Seong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Vaccine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795048/ https://www.ncbi.nlm.nih.gov/pubmed/29399583 http://dx.doi.org/10.7774/cevr.2018.7.1.76 |
Ejemplares similares
-
Progress toward a group B streptococcal vaccine
por: Song, Joon Young, et al.
Publicado: (2018) -
ptsI gene in the phosphotransfer system is a potential target for developing a live attenuated Salmonella vaccine
por: Zhi, Yong, et al.
Publicado: (2020) -
Group A β-hemolytic streptococcal pharyngotonsillitis
outbreak
por: Culqui, Dante R, et al.
Publicado: (2014) -
Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine
por: Jang, A-Yeung, et al.
Publicado: (2021) -
Inhibition of Fibrinolysis by Streptococcal Phage Lysin(SM1)
por: Ji, Hyun Jung, et al.
Publicado: (2021)